(27 days)
The Smartest Persona Blood Glucose Monitoring System, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, nor for use with neonates.
The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.
This system contains a speaking function that provides audible test results for users with low vision.
The Smartest Persona Blood Glucose Monitoring System consists of a blood glucose meter, test strips, control solutions, lancing device, and commercially available lancets. The meter has a bilingual speaking feature that provides audible test results for users with low vision. The forearm may be used as an alternate site for capillary blood.
The provided text is a 510(k) summary for the Smartest Persona Blood Glucose Monitoring System. It describes the device, its intended use, comparison to a predicate device, and the conclusion that it is substantially equivalent. However, it does not include detailed information regarding acceptance criteria, specific performance study results, sample sizes for test or training sets, ground truth establishment, or expert involvement as requested in the prompt.
Therefore, I cannot populate the requested information from the provided text. The document states that "Biotest Medical Corp. has conducted a risk analysis and has performed the necessary verification and validation activities to demonstrate that the design outputs of the modified device meet the design input requirements," but it does not elaborate on what those requirements or the results of those activities were.
{0}------------------------------------------------
510(k) Summary (Per 21 CFR 807.92)
APR - 8 2010
1. Submitter Information
| Company name | Biotest Medical Corporation |
|---|---|
| Contact person | Maggie Chu, President |
| Address | No. 3-2, Chien-Kuo Road, TEPZ, TantzuTaichung 427, TaiwanRepublic of China |
| Phone | 886-919099431 |
| Fax | 886-4-25326593 |
2. Name of Device
| Trade Name | Smartest Persona Blood Glucose Monitoring System |
|---|---|
| Common Name | Blood Glucose Tester |
| Classifications | NBW, Over the Counter Blood Glucose Test, 862.1345 |
| CGA, Glucose Oxidase, 862.1345 | |
| Class II device |
3. Predicate Device
| Trade name | SuperCheck 1 Blood Glucose Monitoring System (SuperCheck 1), |
|---|---|
| Model 6268 | |
| Common name | Blood Glucose Tester |
| Submitter | Biotest Medical Corporation |
| 510(k) number | K091815 |
4. Device Description
The Smartest Persona Blood Glucose Monitoring System consists of a blood glucose meter, test strips, control solutions, lancing device, and commercially available lancets. The meter has a bilingual speaking feature that provides audible test results for users with low vision. The forearm may be used as an alternate site for capillary blood.
5. Intended Use
The Smartest Persona Blood Glucose Monitoring System, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, nor for use with neonates.
{1}------------------------------------------------
The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.
This system contains a speaking function that provides audible test results for users with low vision.
6. Comparison to Predicate Device
Modifications to the cleared device include additional backlight feature and change of one error message from E_7 to E_4. The size and shape of the device have also been modified to differentiate from the predicate. The Smartest Persona Blood Glucose Monitoring System has the same intended use and fundamental scientific technology as the previous version, the SuperCheck 1 Blood Glucose Monitoring System, Model 6268.
7. Performance Studies
Biotest Medical Corp. has conducted a risk analysis and has performed the necessary verification and validation activities to demonstrate that the design outputs of the modified device meet the design input requirements.
8. Conclusion
In summary, the modified Smartest Persona Blood Glucose Monitoring System has the same intended use and fundamental scientific technology as the previous version of the device, which received 510(k) clearance (K091815). Therefore, the subject device is substantially equivalent to the predicate device.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows a logo for the Department of Health & Human Services. The logo features a stylized graphic of an abstract human figure with three curved lines representing the body and head. The text "DEPARTMENT OF HEALTH &" is vertically oriented and wraps around the left side of the logo. The text "HUMAN SERVICES" is vertically oriented and wraps around the right side of the logo.
Biotest Medical Corp. c/o Maggie Chu President No.3-2, Chien-Kuo Road, Tepz, Tantzu Taichung, 427 TW - China (Taiwan)
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
APR 0 8 2010
Re: K100701
Trade/Device Name: Smartest Persona Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name:Glucose test system. Regulatory Class: II Product Code: NBW, CGA Dated: March 10, 2010 Received: March 12, 2010
Dear: Ms. Chu:
.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{3}------------------------------------------------
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
CA
Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: Smartest Persona Blood Glucose Monitoring System
Indications for Use:
The Smartest Persona Blood Glucose Monitoring System, is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the forearm. It is intended for use by healthcare professionals and people with diabetes mellitus at home and as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis or screening for diabetes mellitus, nor for use with neonates.
The alternative site testing (forearm) in this system can only be used during steady-state blood glucose conditions.
This system contains a speaking function that provides audible test results for users with low vision.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use X (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) k/00701
Page 1 of 1
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.